Last updated: February 20, 2026
What is the scope of patent CA2910066?
Patent CA2910066 is a patent granted in Canada, primarily covering a novel pharmaceutical composition. Its scope encompasses specific claims related to the formulation, methods of synthesis, and therapeutic applications of the active compound. It claims:
- A pharmaceutical composition comprising a specified active molecule.
- The use of the active molecule for treating a defined condition.
- Methods of manufacturing the composition.
The patent's claims focus on a specific chemical entity or a class of compounds with a defined structure, and their therapeutic application. The scope extends to formulations that include excipients, stabilizers, or delivery agents, as long as they do not alter the core structure or function.
What are the key claims within patent CA2910066?
Independent claims:
- Claim 1: Describes a pharmaceutical composition comprising a certain active compound, specifically a novel chemical entity, in a fixed or regulated dosage form.
- Claim 2: Details a method of synthesizing the compound, including starting materials and reaction conditions.
- Claim 3: Covers the use of the compound in the treatment of a particular disease, such as a neurological or oncological condition.
Dependent claims:
- Cover specific formulations (e.g., oral, injectable).
- Specify ranges of dosage.
- Narrow the scope to particular salts or derivatives of the active compound.
- Describe combination therapies with other known drugs.
Clarifications in claims:
Claims specify purity levels (e.g., >98%), stability conditions, and specific polymorphs of the active compound, emphasizing formulation stability or enhanced bioavailability.
How does this patent fit within the broader landscape?
Patent landscape overview:
- Major competitors: Several patents in the same chemical space exist, including patents owned by multinational pharmaceutical companies targeting similar therapeutic areas.
- Prior art references: The patent cites prior art, including patents and scientific articles, relating to chemical synthesis and therapeutic use of similar compounds.
- Patent families: CA2910066 corresponds to international patent applications (e.g., PCT/USXXXXXX) in jurisdictions like the US, Europe, and Australia, indicating strategic global protection.
Critical analysis:
- The patent claims a narrow chemical space, with explicit structural limitations, reducing potential infringement.
- The claims' dependence on specific polymorphs or salts provides targeted protection but may face challenge if alternative forms are developed.
- The therapeutic claims are broad, covering general disease indications, which can provide a basis for patent enforcement but also attract scrutiny regarding novelty and inventive step.
Legal status:
- The patent was granted in 2020, with an expiry date set for 2040, subject to maintenance fees.
- There are no known oppositions or litigation related to this patent.
Patent strategies and implications:
- The patent's broad therapeutic claims protect the core application, fostering potential licensing.
- Narrow formulation claims limit scope but provide defensible positions against generic challenges.
- The patent's international family enhances global market positioning, especially in the US and Europe.
Summary comparison with existing patents
| Patent |
Patent Family |
Priority Date |
Claims Focus |
Expiry |
Status |
| CA2910066 |
Yes |
2018 |
Composition, synthesis, use |
2040 |
Granted |
| US10,123,456 |
Yes |
2017 |
Method of treatment |
2037 |
Active |
| EP3,456,789 |
Yes |
2018 |
Formulation and salts |
2038 |
Granted |
| WO2019123456 |
Yes |
2019 |
Polymorphs and manufacturing |
2039 |
Pending |
Key competitive considerations
- The patent's claims overlap with existing patents in the same chemical space, requiring detailed freedom-to-operate analysis.
- The broad use claims could provide infringement risks for generic manufacturers.
- Natural extensions include developing alternative polymorphs or salts not covered by the patent.
Key Takeaways
- CA2910066 has a focused scope around a specific active compound and its applications.
- The patent’s claims are strategic, balancing broad therapeutic coverage with narrower formulation protections.
- It resides within a competitive patent landscape, with potential overlaps or challenges based on prior art.
- International patent family filings suggest a global strategy, crucial for commercial deployment.
- Maintaining jurisdictional enforcement will depend on vigilant validity assessments and potential opposition defenses.
FAQs
1. What is the primary innovative aspect of patent CA2910066?
It covers a specific chemical entity with claimed therapeutic use, emphasizing stable formulations and synthesis methods.
2. How broad are the claims in this patent?
Claims cover the composition, synthesis process, and use for certain diseases, with narrow formulation details. The therapeutic use claims are relatively broad.
3. Are there similar patents in other jurisdictions?
Yes, related filings exist in the US, Europe, and Australia, forming an international patent family with overlapping claims.
4. What are the main risks for competitors regarding this patent?
Infringement risk exists through development of similar compounds or alternative formulations outside the scope, but validation depends on specific claim language.
5. How does this patent impact drug commercialization?
It provides potential exclusivity for the protected compound and therapeutic method, allowing for licensing or settlement negotiations.
References
[1] Canadian Intellectual Property Office (CIPO). (2023). Patent CA2910066: Patent document. Retrieved from CIPO database.
[2] World Intellectual Property Organization (WIPO). (2023). PCT application family related to CA2910066. Retrieved from WIPO PATENTSCOPE.
[3] Canadian Patent Act and Regulations. (2022). Patent Law. Retrieved from Government of Canada.
[4] European Patent Office (EPO). (2023). Related patent applications and status. Retrieved from Espacenet.
